Clinical trials: Plasma Cell Disorder
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Multiple Myeloma
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had…
- Trial name
- NCT05354557
- Testing
- Iberdomide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Relapse After Use of Lenalidomide and Bortezomib
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
Asian patients with relapsed myeloma after prior treatment with bortezomib and lenalidomide will treatment on pomalidomde and dexamethasone. Baseline, follow-up, survival and toxicity information will be collected.
- Trial name
- NCT02158702
- Testing
- Pomalidomide and Dexamethasone
- Where
- 2 sites in Singapore
- Volunteers
- 100 people
- Sponsor
- National University Hospital, Singapore
Multiple Myeloma, Leukemia
Cellular Therapy With Cord Blood Cells
The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Multiple Myeloma, Leukemia, Lymphoma
- Trial name
- NCT00427557
- Testing
- Fludarabine, Melphalan, Umbilical Cord Blood
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
AL Amyloidosis
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
- Trial name
- NCT06649695
- Testing
- Teclistamab
- Where
- 9 sites in Australia, France and 4 more
- Volunteers
- 30 people
- Sponsor
- European Myeloma Network B.V.
Plasma Cell Myeloma
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma.
- Trial name
- NCT04466475
- Testing
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the safety of CCI-779 (Temsirolimus) and bortezomib (Velcade), and the highest dose of this drug that can be given to people safely.
- Trial name
- NCT00483262
- Testing
- CCI-779, Bortezomib
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed and Refractory Multiple Myeloma (RRMM)
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.
- Trial name
- NCT06479954
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00003195
- Testing
- recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first…
- Trial name
- NCT04513639
- Testing
- Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
- Where
- 13 sites in Norway
- Volunteers
- 176 people
- Sponsor
- Oslo University Hospital
AL Amyloidosis
Ixazomib Maintenance Study in Patients With AL Amyloidosis
The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL…
- Trial name
- NCT03618537
- Testing
- Ixazomib, Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extracorporeal Circulation; Complications, Renal Failure
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
During open cardiac surgery, cardiopulmonary bypass (CPB) is used to temporarily replace the function of the heart and lungs. Renal ischemia resulting in acute kidney injury is common after cardiac surgery.
- Conditions
- Extracorporeal Circulation; Complications, Renal Failure, Circulation Disorder, Renal Plasma Flow, Effective
- Trial name
- ICAROX2 (NCT04084301)
- Testing
- High CPB flow
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Sahlgrenska University Hospital
Multiple Myeloma
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions.
- Trial name
- VAMOS (NCT04888039)
- Testing
- quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Toulouse
AL Amyloidosis
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
- Trial name
- NCT07615270
- Testing
- Anselamimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Relapsed/Refractory Multiple Myeloma
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT07760454
- Testing
- CT0596
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- UCARsgen Biotech Limited
Plasmacytoma, Plasmacytoma of Bone
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
- Conditions
- Plasmacytoma, Plasmacytoma of Bone, Multiple Myeloma
- Trial name
- NCT04174196
- Testing
- CC-486, Lenalidomide, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00558896
- Testing
- dexamethasone, pomalidomide
- Where
- 3 sites in United States
- Volunteers
- 378 people
- Sponsor
- Mayo Clinic